Table III.
Characteristic at ART start | Crude HR | 95% CI | p-value | Adjusted HR Full model (N=2 449) |
95% CI | p-value |
---|---|---|---|---|---|---|
WAZ | <0.001* | <0.001* | ||||
>−2 | 1 | 1 | ||||
−3 - −2 | 1.93 | 1.29 - 2.89 | 1.13 | 0.69 - 1.87 | ||
< −3 | 5.23 | 3.84 - 7.12 | 2.44 | 1.65 - 3.59 | ||
Viral load (copies/ml) | <0.001* | 0.010* | ||||
<100 000 | 1 | 1 | ||||
100 000 to 1 million | 1.75 | 1.24 - 2.45 | 1.68 | 1.02 - 2.76 | ||
>1 million | 3.30 | 2.32 - 4.70 | 2.22 | 1.31 - 3.77 | ||
Severe immunosuppression (WHO definition) |
4.23 | 2.55 - 7.00 | <0.001 | 3.83 | 1.68 - 8.72 | 0.001 |
WHO stage 3 or 4 (v. 1 or 2) | 3.01 | 2.00 - 4.54 | <0.001 | 2.16 | 1.28 - 3.62 | 0.004 |
Age | <0.001* | 0.002* | ||||
>3 yrs | 1 | 1 | ||||
1 - 3 yrs | 1.31 | 0.98 - 1.74 | 1.17 | 0.76 - 1.84 | ||
<1 yr | 3.38 | 2.65 - 4.31 | 2.00 | 1.30 - 3.07 | ||
ART commenced before 2006 | 1.28 | 1.02 - 1.60 | 0.036 | 1.68 | 1.18 - 2.39 | 0.004 |
p-values derived from likelihood ratio tests.